HiberGene Diagnostics, a Dublin, Ireland-based company focused on the application of molecular technology to infectious disease testing, raised a first tranche of €1.5m as part of a Series B round of approximately €3.5m.
Backers included undisclosed private investors in Ireland.
The company intends to use the funds to develop and commercialize tests for Group B Streptococcus (GBS), Clostridium difficile and Norovirus, all of which will be launched in 2016.
These tests follow the 2015 launch of HG Meningococcus, a molecular test for bacterial meningitis, and the HG Swift, a platform for running the company’s portfolio of diagnostic tests for human infectious diseases.
HiberGene is led by Brendan Farrell, Chairman & CEO.